Over the past 5 years KBP Biosciences has been steadily growing up its pipeline of new drugs from its base in China. But this morning the biotech company is unveiling a dramatic change of scene, with plans to set up a global headquarters in Philadelphia while taking the wraps off a $76 million venture round that will give its new American CEO the cash to make a splash at the FDA.
Doxepin is a traditional tricyclic antidepressant with analgesic and anesthetic properties when applied topically to the mucosa. Doxepin is one approach in treating insomnia and depression in Parkinson's disease. Patients with Parkinson's disease suffer difficulties in swallowing. Therefore, it was the aim of this study to develop a buccal-adhesive delivery system. Methods: Pectin was modified with cysteine. Stability assays in form of disintegration assay according to the Ph.Eur were performed. Furthermore, bioadhesiveness on buccal mucosa was investigated incorporating the drug doxepin. Results: The adhesiveness was improved 1.4-fold and revealed a sustained release over 3 h. Conclusion: Taking these findings into account, the modifications render this designed excipient fruitful for buccal delivery.
Pernix Figures 1 + 1 + 1 Equals More Than Three with New Zohydro Salesforce
FDA Provides Generic Approval Roadmap for 38 Drugs, Including Vertex`s Kaldeco
Dementia `Linked` to Common Over-The-Counter Drugs